Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 17:15:35 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

Medivir: Funded, Partnered and Still Cheap

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Medivir: Funded, Partnered and Still Cheap

2021-02-09 08:00:00

Redeye believes Medivir’s valuation has been pushed too low. The completed capital raise will provide funding at least throughout 2022. Liver cancer project MIV-818 is arguably still something of a cat in the bag ahead of the imminent Phase Ib update, but earlier observations are promising. A recent licensing deal for birinapant reduces Medivir’s dependence on MIV-818. We reiterate our base case of SEK 15 per share and expect the shares to strengthen following the oversubscribed rights issue.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/